Identification of Graphic Markers of Neurocognitive Disorders (MG)

Last updated: February 22, 2024
Sponsor: Centre integre universitaire de sante et de services sociaux du Centre-Sud-de-l'Île-de-Montréal
Overall Status: Completed

Phase

N/A

Condition

Speech Disorders

Neurologic Disorders

Memory Loss

Treatment

Identification of Graphic Markers

Clinical Study ID

NCT05537688
2023-1632
  • Ages > 50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The diagnosis of neurocognitive disorders such as early Alzheimer's disease (AD) or primary progressive aphasia (PPA) is particularly difficult and constantly evolving, often leading to diagnostic erraticity. However, several studies have shown that graphic parameters are affected in people with moderate to severe Alzheimer's disease. The use of new technologies in the study and analysis of the abilities of people with neurodegenerative diseases is increasingly recommended. The use of a digital tablet with a stylus makes it possible to objectivize the kinematic parameters of writing (pressure, inclination, speed, jerk, time of writing task) and thus would allow a low-cost diffusion of this technology in particular by including it in already existing screening batteries.

The overall objective of the project is to characterize and compare the graphical markers of a writing task, either language-based (writing words, non-words, sentences) or non-language-based (drawing shapes), in patients with PPA, early-stage Alzheimer's disease (i.e., at the stage of minor neurocognitive disorders and major neurocognitive disorders at the beginning of the disease), and in people with no cognitive disorders.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • = > 50 years old For control group :
  • not have a diagnosis of minor or major neurocognitive disorder. For AD :
  • Have mild stage Alzheimer's disease: 1/ Be diagnosed according to ICD-10 criteria forthe following conditions: Alzheimer's disease and 2/ Have an MMSE score between 20 and 27, corresponding to a major TNC of mild stage or have a diagnosis of minor TNC withan MMSE score between 25 and 30, the validity period of a previously done MMSE is 3months. For PPA :
  • Have Primary Progressive Aphasia according to the Gorno-Tempini criteria (Gorno-Tempini et al., 2011) and have an MMSE score between 20 and 27, correspondingto major mild TNC or have a diagnosis of minor TNC with an MMSE score between 25 and 30, the validity period of a previously made MMSE is 3 months.

Exclusion

Exclusion Criteria:

  • Presence of pathologies of the dominant upper limb(s) (left, right or ambidextrouslateralization) disabling such as osteoarthritis, finger amputation, etc.
  • History of stroke.
  • Illiterate person.
  • Participate in a concurrent experimental clinical study, to avoid interference withour study.
  • Not understand oral and written French. The speakers are French-speaking and thelanguage task is performed in French.

Study Design

Total Participants: 53
Treatment Group(s): 1
Primary Treatment: Identification of Graphic Markers
Phase:
Study Start date:
June 27, 2022
Estimated Completion Date:
August 27, 2023

Connect with a study center

  • CRIUGM

    Montréal, Quebec H3W 1W5
    Canada

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.